Neurocrine Biosciences
NBIX
#1591
Rank
A$19.52 B
Marketcap
A$195.86
Share price
-1.38%
Change (1 day)
-19.83%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): A$6.63

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$6.20. In 2024 the company made an earnings per share (EPS) of A$4.87 an increase over its 2023 EPS that were of A$3.66.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)A$6.6336.33%
2024A$4.8733.07%
2023A$3.6657.76%
2022A$2.3269.47%
2021A$1.37-78.21%
2020A$6.28990%
2019A$0.5881.82%
2018A$0.32-113.5%
2017A-$2.350.62%
2016A-$2.3357.28%
2015A-$1.4825.61%
2014A-$1.1818.84%
2013A-$0.99-1085.71%
2012A$0.10

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$2.48-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$1.95-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$29.54 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A$0.04318-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$2.92-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$2.46-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$43.04-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.54-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK